K083111 is an FDA 510(k) clearance for the IMPELLA 5.0 CATHETER FAMILY. Classified as Pump, Blood, Cardiopulmonary Bypass, Non-roller Type (product code KFM), Class II - Special Controls.
Submitted by Abiomed, Inc. (Danvers, US). The FDA issued a Cleared decision on April 16, 2009 after a review of 177 days - an extended review cycle.
This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.4360 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.
View all Abiomed, Inc. devices
NCT00534859
Completed
Interventional
Industry-sponsored
PROTECT I, A Prospective Feasibility Trial Investigating the Use of IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI
PROTECT I, A Prospective Feasibility Trial Investigating the Use of the IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI
| Condition studied |
Patients Undergoing High Risk PCI. |
| Study design |
Single group |
| Eligibility |
All sexes
· 40 Years+
|
| Principal investigator |
William O'Neill, M.D. |
| Sponsor |
Abiomed Inc.
(industry)
|
Started 2006-08-01
→
Primary completion 2010-06-01
→
Completed 2011-03-01
Primary outcome
MACCE Events at 30 days or discharge, whichever is longer
Secondary outcome
Other intra-procedural and peri-procedural adverse events
Study completed - no results published.
This trial concluded in 2011 but has not posted
results to ClinicalTrials.gov. Completed studies without public results are common
in industry-sponsored device trials; the data may be referenced in the
510(k) Summary PDF or remain unpublished.
View full study on ClinicalTrials.gov